Tianmei Zeng

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Aim. To evaluate whether patients with multiple myeloma at various risks can still benefit the same from autologous stem cell transplantation consolidation in the era of novel agents. We retrospectively analyzed 67 consecutive myeloma patients receiving autologous stem cell transplantation after bortezomib and/or thalidomide based inductions. Totally 17(More)
  • 1